Repository logo
 
Publication

Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial

2025-07-01Research article Open access
Simple item page
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorMaurer, Christian
dc.contributor.authorAgostinetto, Elisa
dc.contributor.authorAmeye, Lieveke
dc.contributor.authorLambertini, Matteo
dc.contributor.authorMartel, Samuel
dc.contributor.authorPonde, Noam
dc.contributor.authorBrandão, Mariana
dc.contributor.authorPoggio, Francesca
dc.contributor.authorFerreira, Arlindo
dc.contributor.authorSchiff, Rachel
dc.contributor.authorAngelis, Carmine De
dc.contributor.authorGelber, Richard D.
dc.contributor.authorDent, Susan
dc.contributor.authorThomssen, Christoph
dc.contributor.authorPiccart, Martine
dc.contributor.authorAzambuja, Evandro de
dc.date.accessioned2025-08-05T11:06:42Z
dc.date.available2025-08-05T11:06:42Z
dc.date.issued2025-07-01
dc.description.abstractPurpose There is evidence that statins might improve the outcome of patients with breast cancer. The role of statins in patients with early HER2-positive breast cancer is unknown. Therefore, we explored the association between statin use and survival outcomes in early HER2-positive breast cancer patients in the phase III APHINITY trial (adjuvant pertuzumab/ trastuzumab). Methods All patients (intent-to-treat population, n=4804) were included (6.2 years median follow-up database). The primary objective was to investigate the association of statin use on invasive disease-free survival (IDFS), distant relapse-free interval (DRFI), and overall survival (OS). Patients who received statins at baseline, or started statins within 1 year from randomization were considered statin users. Survival curves were estimated using the Kaplan–Meier method. We used a Cox proportional hazards model for multivariate analysis. Results Overall, 423 (8.8%) patients were classifed as statin users. They were older, more often postmenopausal, had a higher body mass index, more often diabetes, hypertension, coronary heart disease and hyperlipidemia, had smaller sized tumors, were treated more often with breast conserving surgery, and less often with anthracycline-containing regimens. Overall, 508 IDFS events (12.8% among statin users and 10.4% among non-statin users) and 272 deaths (8.5% and 5.4%, respectively) occurred. In multivariate analysis, statin use was not associated with IDFS (HR, 1.11; 95% CI, 0.80–1.52), DRFI (HR, 1.21; 95% CI, 0.81–1.81) nor OS (HR, 1.16; 95% CI, 0.78–1.73). Conclusion In APHINITY, statin use was not associated with improved survival outcomes. These results must be interpreted with caution due to the exploratory nature of the analysis and the associated limitations.eng
dc.identifier.doi10.1007/s10549-025-07699-2
dc.identifier.eid105003782966
dc.identifier.issn0167-6806
dc.identifier.other699c255d-8572-450d-a7d9-da94dff23d75
dc.identifier.pmid40293644
dc.identifier.urihttp://hdl.handle.net/10400.14/54150
dc.identifier.wos001477673700001
dc.language.isoeng
dc.peerreviewedyes
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBreast cancer
dc.subjectHER2-positive
dc.subjectPertuzumab
dc.subjectStatins
dc.subjectTrastuzumab
dc.titleAssociation of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trialeng
dc.typeresearch article
dspace.entity.typePublication
oaire.citation.endPage69
oaire.citation.issue1
oaire.citation.startPage57
oaire.citation.titleBreast Cancer Research and Treatment
oaire.citation.volume212
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
118430605.pdf
Size:
771.06 KB
Format:
Adobe Portable Document Format
Download

Collections

FM - Contribuições em Revistas Científicas / Contribution to Journals